NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Molina sec ...

Core Points - The KinderCare Learning Companies, Inc. is facing a class action lawsuit related to its October 2024 IPO, with a deadline for lead plaintiff appointment set for October 14, 2025 [1][6] - The lawsuit alleges that the IPO registration statement was misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, and that the company did not meet industry standards for child care [4][5] - Following the IPO, KinderCare's stock price has significantly declined, dropping to around $9 per share from the IPO price of $24 [3][5] Company Overview - KinderCare provides early education and child care services across the United States, having raised $648 million through the sale of over 27 million shares during its IPO [3] - The company is accused of exposing itself to undisclosed risks, including potential lawsuits and reputational damage due to inadequate care at its facilities [4] Legal Context - The class action lawsuit is being led by Robbins Geller Rudman & Dowd LLP, a prominent law firm specializing in securities fraud and shareholder litigation [7] - The Private Securities Litigation Reform Act of 1995 allows investors who purchased KinderCare stock in or traceable to the IPO to seek lead plaintiff status, which enables them to represent the interests of the class [6]

Core Viewpoint - A class action securities lawsuit has been filed against Dow Inc. alleging securities fraud that negatively impacted investors between January 30, 2025, and July 23, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Dow Inc. overstated its ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [2]. - It is alleged that the true extent of negative impacts from competitive pressures, declining global sales, and product oversupply was understated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Group 1 - Fortress Biotech Inc. is under investigation by Pomerantz LLP for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, received a Complete Response Letter (CRL) from the U.S. FDA regarding the New Drug Application for CUTX-101, citing cGMP deficiencies at the manufacturing facility [1] - Following the announcement of the CRL, Fortress's stock price dropped by $1.14 per share, representing a decline of 30.81%, closing at $2.56 per share on the same day [1] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85 years of operation [2]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Palantir Technologies Inc. regarding potential securities fraud or unlawful business practices [1] - An internal U.S. Army memo reported that Palantir's NGC2 platform is considered "very high risk" due to security vulnerabilities, leading to a significant drop in Palantir's stock price [1] Group 1: Investigation Details - The investigation focuses on whether Palantir and its officers or directors have engaged in securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [1] Group 2: Stock Market Impact - Following the news of the security vulnerabilities, Palantir's stock price fell by $13.98 per share, or 7.47%, closing at $173.07 per share on October 3, 2025 [1]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Braskem S.A. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On September 26, 2025, Braskem announced it has retained financial and legal advisors to explore economic-financial alternatives to optimize its capital structure [1] - Following the announcement, Braskem's American Depositary Receipt (ADR) price fell by $0.45, or 14.71%, closing at $2.61 per ADR on the same day [1]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of The Hain Celestial Group, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] Group 1: Financial Performance - On September 15, 2025, Hain reported disappointing financial results for the fourth quarter and fiscal year 2025, leading to a significant drop in stock price [1] - The interim Chief Executive Officer acknowledged the company's performance did not meet expectations and stated that decisive actions are being taken to optimize cash, deleverage the balance sheet, stabilize sales, and improve profitability [1] - Following the announcement, Hain's stock price fell by $0.53 per share, or 24.65%, closing at $1.62 per share [1] Group 2: Legal Investigation - Pomerantz LLP, a firm known for its expertise in corporate, securities, and antitrust class litigation, is leading the investigation into Hain's practices [1] - The firm has a long history of fighting for the rights of victims of securities fraud and has recovered numerous multimillion-dollar damages awards on behalf of class members [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Larimar Therapeutics, Inc. following a significant stock price drop after the release of clinical trial data [1] Group 1: Company Overview - Larimar Therapeutics, Inc. is publicly traded on NASDAQ under the ticker LRMR [1] - The company is currently conducting a long-term open-label study on Nomlabofusp for treating Friedreich's Ataxia [1] Group 2: Recent Developments - On September 29, 2025, Larimar announced "positive" data from its ongoing study, but also reported seven cases of anaphylaxis among participants [1] - Following the announcement, Larimar's stock price decreased by $1.72, representing a 33.66% decline, closing at $3.38 per share [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sina Corporation and certain executive officers, alleging that they engaged in fraudulent practices to depress the value of Sina's ordinary shares during a take-private acquisition [1][2][3]. Group 1: Lawsuit Details - The class action is on behalf of investors who sold Sina ordinary shares between October 13, 2020, and March 22, 2021, known as the Class Period [1][2]. - Investors have until November 18, 2025, to request to be appointed as Lead Plaintiff for the class [2]. Group 2: Allegations Against Defendants - The lawsuit claims that the defendants misrepresented and omitted material information in Sina's proxy materials related to the Merger, which was necessary for shareholders to make informed decisions [3]. - Specific allegations include the concealment of the true value of Sina's investment in TuSimple Holdings, Inc., and that the offered price of $43.30 per ordinary share significantly undervalued Sina's shares [3].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics regarding potential securities fraud or unlawful business practices [1] - MoonLake reported disappointing results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [1] - Following the trial results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [1] Company Overview - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX [1] - The company is involved in the development of immunotherapeutic treatments, specifically focusing on sonelokimab [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [2]